Publication:
Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC)

Simple item page
dc.contributor.authorPuerta, JM
dc.contributor.authorJiménez Velasco, A
dc.contributor.authorGarcía, MJ
dc.contributor.authorMolina, JR
dc.contributor.authorRuiz, C
dc.contributor.authorFerrer, C
dc.contributor.authorDurán, MS
dc.contributor.authorSimón, I
dc.contributor.authorClavero, E
dc.contributor.authorAvellaneda, MC
dc.contributor.authorRosell, A
dc.contributor.authorBallesteros, I
dc.contributor.authorRamírez, S
dc.contributor.authorPortero, MA
dc.contributor.authorRamírez, MJ
dc.contributor.authorFernández, M
dc.contributor.authorJiménez, M
dc.contributor.authorFe, R
dc.contributor.authorMulero, N
dc.contributor.authorLópez, P
dc.contributor.authoraffiliation[Puerta,JM] Hematology, Complejo Hospitalario Universitario de Granada, Granada. [Jiménez Velasco,A; Ruiz,C] Hospital Regional Universitario Carlos Haya, Málaga. [García,MJ] Complejo Hospitalario Torrecardenas,Almeria. [Molina,JR] Hospital Reina Sofia, Cordoba. [Ferrer,C] Hospital Comarcal San Juan de la Cruz, Ubeda. [Durán,MS] Complejo Hospitalario de Jaen, Jaen. [Simón,I] Hospital Nuestra Senora de Valme, Sevilla. [Clavero,E] Hospital Comarcal Santa Ana, Motril. [Avellaneda,MC] Hospital Comarcal San Agustin, Linares. [Rosell,A] Hematology, Hospital Universitario Virgen de la Victoria, Malaga. [Ballesteros,I] Hospital Comarcal de la Axarquia, Velez-Malaga. [Ramírez,S] Hospital Juan Ramon Jimenez, Huelva. [Portero,MA] Hematology, Hospital Universitario Virgen de Macarena, Sevilla. [Ramírez,MJ] Hospital de Jerez de la Frontera, Jerez de la Frontera. [Fernández,M] Hospital Infanta Margarita, Cabra. [Jiménez,M] Hospital General de Riotinto, Riotinto. [Fe,R] Hospital Punta de Europa, Algeciras. [Mulero,N] Hospital de la Linea, La Linea de la Concepcion. [López,P] Complejo Hospitalario Universitario de Granada, Granada, Spain.es
dc.date.accessioned2016-10-03T12:13:25Z
dc.date.available2016-10-03T12:13:25Z
dc.date.issued2016-06
dc.description.abstractEven though they were approved last June 2011 to be used on first line, it is not a common procedure to begin treatment of CML-CP with 2GTKI, despite it has been demonstrated its efficacy and safety against imatinib on ENESTnd and Dasision clinical trials.es
dc.description.versionNoes
dc.identifier.citationPuerta JM, Jiménez Velasco A, García MJ, Molina JR, Ruiz C, Ferrer C, et al.Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC). Haematologica. 2016; 101(s1).PB1820es
dc.identifier.essn1592-8721
dc.identifier.issn0390-6078
dc.identifier.urihttp://hdl.handle.net/10668/2445
dc.journal.titleHaematologica
dc.language.isoen
dc.organizationAGS Campo de Gibraltar Oeste
dc.organizationAGS Este de Málaga-Axarquía
dc.organizationAGS Norte de Huelva
dc.organizationAGS Norte de Jaén
dc.organizationAGS Sur de Córdoba
dc.organizationAGS Sur de Granada
dc.organizationAGS Jerez, Costa Noroeste y Sierra de Cádiz
dc.publisherFerrata Storti Foundationes
dc.relation.publisherversionhttp://www.haematologica.org/content/101/s1es
dc.rights.accessRightsopen access
dc.subjectDasatinibes
dc.subjectHumanoses
dc.subjectMesilato de imatinibes
dc.subjectLeucemia mielogenosa crónica BCR-ABL positivaes
dc.subjectPirimidinases
dc.subjectSistema de registroses
dc.subjectAndalucíaes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Thiazoles::Dasatinibes
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Benzamides::Imatinib Mesylatees
dc.subject.meshMedical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positivees
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidineses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registrieses
dc.titleEfficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC)es
dc.typeconference presentation
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PuertaJM_EfficacyAndSafety.pdf
Size:
61.25 KB
Format:
Adobe Portable Document Format
Description:
Abstract
Download

Collections

SAS - Hospital Universitario Regional de Málaga
SAS - Hospital de La Axarquía
SAS - Hospital de Riotinto
SAS - Hospital Infanta Margarita
SAS - Hospital Punta de Europa
SAS - Hospital San Agustín
Load more

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía